U.S. Markets open in 1 hr 3 mins

Why the stock of this small biotech with an underdog cancer drug climbed 46%

·3 min read
Why the stock of this small biotech with an underdog cancer drug climbed 46%
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Gilead Sciences, which sold the drug for $3 million less than three years ago, still could come out a winner if the drug is approved by the FDA for patients with the blood cancer myelofibrosis.